1. Home
  2. CASI vs AKTX Comparison

CASI vs AKTX Comparison

Compare CASI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • AKTX
  • Stock Information
  • Founded
  • CASI 1991
  • AKTX N/A
  • Country
  • CASI China
  • AKTX United States
  • Employees
  • CASI N/A
  • AKTX N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASI Health Care
  • AKTX Health Care
  • Exchange
  • CASI Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • CASI 33.4M
  • AKTX 29.1M
  • IPO Year
  • CASI 1996
  • AKTX N/A
  • Fundamental
  • Price
  • CASI $1.94
  • AKTX $1.21
  • Analyst Decision
  • CASI Strong Buy
  • AKTX
  • Analyst Count
  • CASI 1
  • AKTX 0
  • Target Price
  • CASI $4.00
  • AKTX N/A
  • AVG Volume (30 Days)
  • CASI 13.6K
  • AKTX 15.4K
  • Earning Date
  • CASI 05-13-2025
  • AKTX 04-16-2025
  • Dividend Yield
  • CASI N/A
  • AKTX N/A
  • EPS Growth
  • CASI N/A
  • AKTX N/A
  • EPS
  • CASI N/A
  • AKTX N/A
  • Revenue
  • CASI $28,537,000.00
  • AKTX N/A
  • Revenue This Year
  • CASI $66.12
  • AKTX N/A
  • Revenue Next Year
  • CASI $51.37
  • AKTX N/A
  • P/E Ratio
  • CASI N/A
  • AKTX N/A
  • Revenue Growth
  • CASI N/A
  • AKTX N/A
  • 52 Week Low
  • CASI $1.88
  • AKTX $0.85
  • 52 Week High
  • CASI $7.67
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • CASI 41.12
  • AKTX 52.68
  • Support Level
  • CASI $1.91
  • AKTX $1.06
  • Resistance Level
  • CASI $2.14
  • AKTX $1.27
  • Average True Range (ATR)
  • CASI 0.20
  • AKTX 0.11
  • MACD
  • CASI -0.01
  • AKTX -0.01
  • Stochastic Oscillator
  • CASI 11.11
  • AKTX 72.22

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Share on Social Networks: